iwCLL 2019 – facilitating the development of novel agents and treatment outcomes
Mary Ann Anderson
Will knowledge of the molecular pathology of lymphoma improve clinical trials?
David Maloney et al.
Current landscape and future prospects for Hodgkin lymphoma treatment
Martin Hutchings • 18 Mar 2018
Investigating melflufen: a peptidase enhanced cytotoxic for myeloma
Paul Richardson • 14 Jun 2018